Amarin (AMRN) Cut to "Sell" at Zacks Investment Research


According to Zacks, "Amarin Corporation plc is a global pharmaceutical group which develops innovative pharmaceutical products across a range of therapeutic areas utilizing its proprietary advanced oral and transdermal drug delivery technologies. " Other research analysts have also recently issued research reports about the company.



from Biotech News